BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15634723)

  • 1. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease.
    Ziegler S; Mittermayer F; Plank C; Minar E; Wolzt M; Schernthaner GH
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2175-8. PubMed ID: 15634723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
    Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
    Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
    Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.
    Böger RH; Lentz SR; Bode-Böger SM; Knapp HR; Haynes WG
    Clin Sci (Lond); 2001 Feb; 100(2):161-7. PubMed ID: 11171285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.
    Stühlinger MC; Oka RK; Graf EE; Schmölzer I; Upson BM; Kapoor O; Szuba A; Malinow MR; Wascher TC; Pachinger O; Cooke JP
    Circulation; 2003 Aug; 108(8):933-8. PubMed ID: 12912818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia.
    Manns B; Hyndman E; Burgess E; Parsons H; Schaefer J; Snyder F; Scott-Douglas N
    Kidney Int; 2001 Mar; 59(3):1103-9. PubMed ID: 11231366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
    Sydow K; Böger RH
    Z Kardiol; 2001 Jan; 90(1):1-11. PubMed ID: 11220081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
    Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.
    Manns BJ; Burgess ED; Hyndman ME; Parsons HG; Schaefer JP; Scott-Douglas NW
    Am J Kidney Dis; 1999 Oct; 34(4):669-77. PubMed ID: 10516348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients].
    Wu CJ; Wang L; Li X; Wang CX; Ma JP; Xia XS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Dec; 40(12):1003-8. PubMed ID: 23363713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
    Stühlinger MC; Stanger O
    Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
    Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
    Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke.
    Yoo JH; Lee SC
    Atherosclerosis; 2001 Oct; 158(2):425-30. PubMed ID: 11583722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial.
    Sesmilo G; Biller BM; Llevadot J; Hayden D; Hanson G; Rifai N; Klibanski A
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1518-24. PubMed ID: 11297577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina.
    Guo H; Chi J; Xing Y; Wang P
    Indian J Med Res; 2009 Mar; 129(3):279-84. PubMed ID: 19491420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocyst(e)inemia--determining factors and treatment.
    Genest J
    Can J Cardiol; 1999 Apr; 15 Suppl B():35B-38B. PubMed ID: 10350684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.
    Henning BF; Zidek W; Riezler R; Graefe U; Tepel M
    Res Exp Med (Berl); 2001 Mar; 200(3):155-68. PubMed ID: 11426667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease.
    Schmitt B; Wolters M; Kressel G; Hülsmann O; Ströhle A; Kühn-Velten WN; Lichtinghagen R; Bub A; Barth SW; Stichtenoth DO; Hahn A
    Atherosclerosis; 2007 Jul; 193(1):168-76. PubMed ID: 16876171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension?
    Virdis A; Ghiadoni L; Salvetti G; Versari D; Taddei S; Salvett A
    J Nephrol; 2002; 15(4):414-21. PubMed ID: 12243373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.